China’s Haisco Pharmaceutical Group has entered into a significant licensing and research collaboration with Eli Lilly, valued at $2.9 billion, aimed at developing innovative medicines across various therapeutic areas. Under this agreement, Haisco will identify up to five target programs, while Lilly will manage clinical development and commercialization. Lilly gains exclusive rights to specific programs globally, whereas Haisco retains rights in its designated territories. Haisco stands to receive up to $87 million initially, along with potential milestone payments and royalties from future sales. This marks the first collaboration between the two companies, aiming to accelerate the development of new therapeutics.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biospectrumasia.com/news/25/27732/chinas-haisco-pharma-inks-2-9-b-deal-with-eli-lilly-focusing-on-multiple-therapeutic-areas.html
